Organon & Co. (NYSE:OGN) Receives Average Rating of "Hold" from Analysts

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have been assigned a consensus rating of "Hold" from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.80.

Several equities analysts recently commented on the stock. Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday. Morgan Stanley decreased their price target on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a report on Friday. Finally, TD Cowen raised shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th.

Organon & Co. Stock Up 1.1 %

NYSE OGN traded up $0.18 on Friday, hitting $15.46. The stock had a trading volume of 3,414,065 shares, compared to its average volume of 2,844,831. The business's fifty day moving average price is $15.36 and its 200 day moving average price is $17.34. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 3.07, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Equities research analysts anticipate that Organon & Co. will post 3.82 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be given a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.25%. Organon & Co.'s dividend payout ratio is presently 22.22%.

Hedge Funds Weigh In On Organon & Co.

A number of institutional investors have recently modified their holdings of the stock. Barclays PLC boosted its stake in shares of Organon & Co. by 238.0% in the third quarter. Barclays PLC now owns 119,483 shares of the company's stock worth $2,285,000 after buying an additional 84,136 shares during the last quarter. Weiss Asset Management LP acquired a new position in Organon & Co. in the third quarter valued at approximately $32,966,000. Cerity Partners LLC lifted its holdings in Organon & Co. by 94.0% in the third quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock valued at $12,766,000 after acquiring an additional 323,308 shares during the period. Foundry Partners LLC purchased a new stake in Organon & Co. in the 3rd quarter worth approximately $7,642,000. Finally, Beddow Capital Management Inc. grew its stake in shares of Organon & Co. by 38.8% during the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company's stock worth $5,867,000 after purchasing an additional 85,775 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.